Details for Patent: 11,752,106
✉ Email this page to a colleague
Which drugs does patent 11,752,106 protect, and when does it expire?
Patent 11,752,106 protects KALYDECO and TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has twenty patent family members in thirteen countries.
Drugs Protected by US Patent 11,752,106
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-004 | May 3, 2023 | RX | Yes | No | 11,752,106 | ⤷ Subscribe | Y | TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO | ⤷ Subscribe | |||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-005 | May 3, 2023 | RX | Yes | No | 11,752,106 | ⤷ Subscribe | Y | TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO | ⤷ Subscribe | |||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | 11,752,106 | ⤷ Subscribe | Y | TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,752,106
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013226076 | ⤷ Subscribe | |||
| Brazil | 112014021090 | ⤷ Subscribe | |||
| Canada | 2865519 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
